Expects to end 2025 at ~2.8x. Says entering “exciting period” for biosimilar portfolio. Says has made “significant progress” with transformation program. Says set to deliver on 2027 targets. Comments taken from Q3 earnings conference call.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: